ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Respiratory · Respir Med · 2026-10-16

In 314 patients with COPD, nebulised glycopyrronium/formoterol/budesonide twice daily was non-inferior to the same triple combination by MDI for change in trough FEV1 at 12 weeks (difference -0.00 L, 95% CI -0.04 to 0.04); adverse events were comparable.

RCTn = 314
Kodgule et al. Efficacy and safety of novel nebulized combination of glycopyrronium, formoterol and budesonide in comparison with metered dose inhaler of glycopyrronium, formoterol and budesonide in COPD - A randomized, double-blind, double-dummy clinical trial
Gastroenterology · Clin Gastroenterol Hepatol · 2026-04-14

Network meta-analysis of 13 RCTs in eosinophilic oesophagitis (age ≥12): dupilumab ranked highest for dysphagia at 12 and 24 weeks and budesonide orodispersible tablets 1 mg at 48 weeks; all agents except etrasimod gave histologic remission vs placebo.

Meta-analysisn = 13 trials
Al Hayek et al. Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients With Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis With Meta-Regression
Ear, nose and throat · Int Forum Allergy Rhinol · 2026-02-13

Randomised trial in 52 surgically naive patients with chronic rhinosinusitis with nasal polyps: 4 weeks of budesonide nasal irrigation improved SNOT-22 more than saline (mean difference 18.1 points, p = 0.017), with no difference in smell testing.

RCTn = 52
Sant'Ana et al. Effect of Budesonide Nasal Irrigation in Patients With Chronic Rhinosinusitis With Nasal Polyps Without Prior Sinus Surgery: A Randomized, Double-Blind, Placebo-Controlled Study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.